All Updates

All Updates

icon
Filter
Funding
Phenomix Sciences raises USD 5.5 million in Series A funding and USD 2.3 million in grant funding to accelerate commercialization and adoption of MyPhenome test
Precision Medicine
May 16, 2024
This week:
Funding
Lhyfe receives EUR 11 million grant from Klimatklivet for green hydrogen project in Sweden
Hydrogen Economy
Yesterday
Product updates
XRAI Glass launches AR One glasses at USD 1449 for hearing-impaired individuals
Extended Reality
Yesterday
Funding
VR therapy platform CUREosity raises EUR 3.8 million in funding to expand market presence
Extended Reality
Yesterday
Last week:
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Decentralized Finance (DeFi)
Jun 22, 2024
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Web3 Ecosystem
Jun 22, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Data Infrastructure & Analytics
Jun 21, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Foundation Models
Jun 21, 2024
Partnerships
Product updates
Anthropic releases Claude 3.5 Sonnet, the first model in the 3.5 series
Foundation Models
Jun 21, 2024
Funding
Paramount Planet Product raises USD 1 million in federal grant funding to support commercialization
Bio-based Materials
Jun 21, 2024
Regulation/policy
Apple delays launch of Apple Intelligence features in EU citing regulatory concerns
Generative AI Applications
Jun 21, 2024
Precision Medicine

Precision Medicine

May 16, 2024

Phenomix Sciences raises USD 5.5 million in Series A funding and USD 2.3 million in grant funding to accelerate commercialization and adoption of MyPhenome test

Funding

  • Phenomix Sciences has raised USD 5.5 million in a Series A funding round, with participation from existing investor Health2047 and new investors DexCom Inc. and Labcorp. Additionally, the company received a USD 2.3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

  • The raised funds are expected to accelerate the commercialization of the MyPhenome test in the sector of obesity specialists and the broader industry. The test is claimed to identify obesity phenotypes and provide physicians with tools to create effective treatment plans, including lifestyle and diet interventions, as well as medication and procedure recommendations.

  • Phenomix Sciences is a biotechnology company focused on precision medicine for obesity treatment. It leverages genetic testing and data analytics to categorize obesity into phenotypes, which enables personalized treatment plans to optimize outcomes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.